GammaTile Therapy for Brain Tumors Significantly Improves Survival, Study Shows
A targeted therapy for brain tumors offered regionally only at Albany Medical Center is shown to significantly lower rates of tumor regrowth and significantly improve overall survival compared to current standard treatment, according to results from the Radiation One and Done (ROADS) Phase III Clinical Trial published recently in the Journal of Clinical Oncology.
One of 32 centers across the United States to participate in the ROADS trial, Albany Medical Center began offering GammaTile Therapy in 2023. The postage-stamp-sized tile, which is embedded with small radiation sources, is implanted in the last five minutes of surgery to remove a brain tumor. The radiation immediately begins targeting tumor cells in the area where the tumor is most likely to recur. Over time and after the radiation has been delivered, the collagen tile naturally dissolves into the surrounding tissue.
The previous standard of care for patients with operable brain tumors is surgical removal of the tumor followed by adjuvant therapy, including radiation and chemotherapy. Traditional radiation cannot begin until surgical recovery and is delivered in as many as 30 treatments extending over a period of several weeks, causing a substantial burden of treatment for patients and their caregivers alike.
The ROADS trial randomized 230 patients to GammaTile tile-based radiation therapy or standard stereotactic radiation therapy following tumor removal surgery. Data from the trial highlights the benefits of beginning radiation at the time of surgery and eliminating the weeks-long delay needed for standard radiation therapy.
Key findings of the ROADS trial show:
• Drastic Reduction in Tumor Recurrence: Patients treated with GammaTile experienced a 98.7% local tumor control rate at 12 months compared to 84.6% for those receiving standard-of-care stereotactic radiation therapy (SRT), lowering the risk of local recurrence by over 90%.
• Significantly Prolonged Survival: Treatment with GammaTile nearly doubled median overall survival to 42.5 months, compared to just 17.6 months for the standard SRT cohort.
• Halved Risk of Recurrence or Death: GammaTile achieved a 52% reduction in the combined risk of surgical bed recurrence or death (Surgical Bed Recurrence-Free Survival) compared to standard-of-care treatments.
“Albany Medical Center’s participation in this groundbreaking clinical trial reflects our commitment to improving patient outcomes and to offering the most innovative and advanced treatments for patients with brain tumors,” said Alexandra Paul, MD, neurosurgeon at Albany Medical Center. “We are optimistic about the positive results of this study, and we are pleased to offer our patients another treatment option after receiving a difficult brain tumor diagnosis.”
“Our goal is always to maximize treatment benefits while maintaining our patients’ quality of life” said Edward Farhangi, MD, chair of the Department of Radiation Oncology at Albany Medical Center. “To see a marked improvement in overall survival while decreasing the burden of repeated radiation appointments is what makes our participation in clinical research so rewarding.”
For more information about the ROADS trial results, visit https://gammatile.com/hcp/resource-center/roads-trial-media-resources/.
For more information or to contact Albany Medical Center’s Neurosurgery Department, call 518-262-5088 or visit https://www.albanymed.org/specialty/brain-tumors/.